Drug intelligence / Profile preview

XP-828L

Development stage: Unknown
Lead developer: Advitech
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

XP-828L is an orally administered, growth factor-enriched protein extract derived from bovine sweet whey, developed by Advitech for the treatment of mild to moderate psoriasis. Commercialized under the brand name Dermylex, it is classified as a nutraceutical or natural health product. The compound exhibits immunomodulatory properties; in vitro studies have shown that it inhibits the proliferation of T-cells (specifically ConA-stimulated splenocytes) and modulates cytokine production. Clinical trials have demonstrated that daily oral intake of XP-828L (ranging from 800 mg to 5 g) significantly improves Physician's Global Assessment (PGA) scores and reduces disease severity in patients with psoriasis.

Brand names: Dermylex
Other names: Sweet whey protein extractBovine milk protein extract

Beyond the preview

Go deeper on XP-828L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XP-828L.

Explore the full profile